Revvity Stock Rises on Q1 Beat Despite Lowered Guidance

Key Highlights

Revvity Inc. (RVTY) reported first-quarter adjusted earnings of $1.06 per share, surpassing analyst expectations of $1.02. Despite the positive earnings surprise, the company has lowered its adjusted profit guidance for the full year 2026.

Company Performance Overview

The medical equipment maker's stock saw a 2.7% increase in premarket trading following the announcement. The company also revealed its decision to sell its immunodiagnostics business in China, a segment representing about 6% of its projected fiscal 2025 total revenue. Prior to this session, the stock was down 10.6% year-to-date.

Market and Forecast Impact

The lowered guidance for 2026, now projected at $5.20 to $5.30 per share from a previous $5.35 to $5.45, fell below the analyst consensus of $5.39. This adjustment reflects strategic changes, including the divestiture of its China-based business unit, signaling a shift in the company's long-term strategy.

Summary and Outlook

While the Q1 earnings beat provided a short-term boost to Revvity's stock, investors will be closely watching the impact of the lowered long-term forecast and the strategic sale of its Chinese business. The market's reaction suggests a mixed sentiment, balancing current performance against future uncertainty.

FAQ

Q: Why did Revvity's stock increase?
A: The stock rose because its first-quarter adjusted profit of $1.06 per share beat Wall Street's estimate of $1.02.

Q: What was the change in Revvity's future guidance?
A: Revvity lowered its 2026 adjusted profit guidance to a range of $5.20 to $5.30 per share, down from its previous forecast.

Source: Investing.com